Slide 1: Second Quarter 2024 Financial Results Conference Call
Second Quarter 2024 Financial Results Conference Call August 1, 2024
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Operating Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 4: Generated $200M in 2Q 2024 revenues, including $180M in U.S. net product sales
Generated $200M in 2Q 2024 revenues, including $180M in U.S. net product sales On track to become a multi-billion-dollar Transforming SOC for patients with PNH U.S. product ✓ ~$24.5M in 2Q 2024 U.S. net product ✓ ~$155M in 2Q 2024 U.S. net product revenue revenue, a 12% increase QoQ ✓ 97% compliance
Slide 5: SYFOVRE remains market leader in the U.S.
SYFOVRE remains market leader in the U.S. ✓ >84k SYFOVRE doses delivered to ECP practices in 2Q 20241 ✓ >330k SYFOVRE injections estimated to have been administered as of June 2024 (incl. clinical trials)2 ✓ >2,100 sites of care ordered SYFOVRE LTD ✓ Retinal vasculitis remains rare and appears to be
Slide 6: GA market opportunity is large and growing
GA market opportunity is large and growing SYFOVRE market leadership: ~1.5M GA patients ✓ Increasing effects over time estimated in U.S. 1 ✓ Well-documented safety profile ✓ Flexible dosing ✓ Unmatched clinical dataset GA patients currently diagnosed ✓ Extensive real-world experience and in ECP offi
Slide 7: EMPAVELI continues to elevate the standard of care in PNH
EMPAVELI continues to elevate the standard of care in PNH As of June 30, 2024: • ~$24.5 million in 2Q 2024 U.S. net product sales • ~97% patient compliance rate • Continued strong safety profile 7
Slide 8: SYFOVRE: first approved GA therapy to show visual function benefit in prespecified analysis
SYFOVRE: first approved GA therapy to show visual function benefit in prespecified analysis Number of Scotomatous Points on Microperimetry Mean Change from Baseline Favors Sham (0-24m) / vs Sham/Sham Crossover (95% CI) Favors Pegcetacoplan Crossover (24-36m) -0.34 (-2.11, 1.43) Month 18 -0.39 (-2.22
Slide 9: C3G and IC-MPGN: two debilitating kidney diseases
C3G and IC-MPGN: two debilitating kidney diseases • Rare kidney diseases with no approved therapies • Progress to kidney failure in ~50% of patients within 5-10 years of diagnosis ‒ Leads to kidney transplant or lifelong dialysis, neither curative Chase Living with C3G • ~5,0001 people with C3G/IC-M
Slide 10: VALIANT Phase 3 study: top-line data expected August 2024
VALIANT Phase 3 study: top-line data expected August 2024 Primary endpoint readout Up to 10 weeks 26 weeks 26 weeks 8 weeks Population: Patients 12 Screening Randomized, double-blind Open-label period Follow-up1 years+ with C3G or primary placebo-controlled period IC-MPGN pre- and post- transplant a
Slide 11: Consolidated second quarter 2024 financial results
Consolidated second quarter 2024 financial results (In USD Millions) Three Months Ended June 30, 2024 2023 EMPAVELI U.S. Net Product Sales $24.5 $22.3 SYFOVRE U.S. Net Product Sales 154.6 67.3 Licensing and Other Revenue 20.5 5.3 Total Revenue $199.7 $95.0 Cost of Sales 23.1 8.4 Expenses R&D Expense
Slide 12: On path to become cash flow positive without relying on capital markets to fund core business
On path to become cash flow positive without relying on capital markets to fund core business Strategic, non-dilutive refinancing collaboration with Sixth Street Up to $475 million in funding Debt-neutral to Apellis Principal repayment is pushed out to May 2030 Provides flexibility to access ≥$200M
Slide 13: Second Quarter 2024 Financial Results Conference Call
Second Quarter 2024 Financial Results Conference Call August 1, 2024